Articles From: Bing shares the top searches of 2014 to Biocept and Rosetta Genomics Collaborate to Evaluate microRNAs From Circulating Tumor Cells


2014/11/30
Bing outlines the people, moments and events that shaped 2014 at http://www.BingTrends.com. REDMOND, Wash.
Sign-up for Bing shares the top searches of 2014 investment picks
TEL AVIV, Israel, Nov.
Sign-up for Bio Blast Pharma Reports Third Quarter Financial Results investment picks
Bio-Path Holdings, Inc., (NASDAQ:BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced the appointment of Amy P.
Sign-up for Bio-Path Holdings Appoints Amy P. Sing, M.D. to its Board of Directors investment picks
Bio-Path Holdings, Inc., (NASDAQ:BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the third quarter ended September 30, 2014.
Sign-up for Bio-Path Holdings Reports Third Quarter 2014 Operational and Financial Results investment picks
Bio-Path Holdings, Inc., (NASDAQ:BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has initiated development of Liposomal Bcl-2 as a treatment for follicular lymphoma.
Sign-up for Bio-Path Holdings to Initiate Development of Liposomal Bcl-2 in Follicular Lymphoma investment picks
Bio-Path Holdings, Inc., (NASDAQ:BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that Peter Nielsen, President and Chief Executive Officer, will present a company overview at the Biotech Showcase™ 2015 Conference in San Francisco, CA on Tuesday, January 13, 2015 at 3:30 p.m. Pacific Time.
Sign-up for Bio-Path Holdings to Present at the Biotech Showcase™ 2015 Conference investment picks
Bio-Path Holdings, Inc., (NASDAQ:BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that data from pre-clinical studies of BP-100-1.01 (Liposomal Grb-2) were featured in the peer-reviewed journal Expert Opinion on Drug Delivery.
Sign-up for Bio-Path Holdings’ Liposomal Grb-2 Featured in Peer-Reviewed Journal “Expert Opinion on Drug Delivery” investment picks
http://media.marketwire.com/attachments/201308/181926_BIO-RADLOGO.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1155901&ProfileId=051205&sourceType=1 HERCULES, CA --
Sign-up for Bio-Rad Laboratories Resolves Foreign Corrupt Practices Act Matters With U.S. Government investment picks
http://media.marketwire.com/attachments/201308/181926_BIO-RADLOGO.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1159948&ProfileId=051205&sourceType=1 HERCULES, CA --
Sign-up for Bio-Rad Receives Premarket Application Approval for Its Geenius HIV 1/2 Supplemental Assay investment picks
http://media.marketwire.com/attachments/201308/181926_BIO-RADLOGO.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1156358&ProfileId=051205&sourceType=1 HERCULES, CA --
Sign-up for Bio-Rad Reports Third-Quarter 2014 Financial Results investment picks
MINNEAPOLIS , Nov.
Sign-up for Bio-Techne Announces Agreement To Acquire CyVek investment picks
MINNEAPOLIS , Oct.
Sign-up for Bio-Techne Declares Dividend investment picks
MINNEAPOLIS , Oct.
Sign-up for Bio-Techne Releases First Quarter Fiscal 2015 Results investment picks
BioAmber Announces New Chief Financial Officer and Change to the Board Canada NewsWire MINNEAPOLIS, MN , Jan.
Sign-up for BioAmber Announces New Chief Financial Officer and Change to the Board investment picks
MINNEAPOLIS, MN , Jan.
Sign-up for BioAmber Announces New Chief Financial Officer and Change to the Board investment picks
MINNEAPOLIS, MN , Dec.
Sign-up for BioAmber Refinances $25 Million Loan investment picks
MINNEAPOLIS, MN , Nov.
Sign-up for BioAmber Reports Third Quarter 2014 Financial Results investment picks
5 year supply agreement is with Oleon, a European leader in oleochemicals BioAmber bio-succinic acid is being used to produce bio-based lubricants Oleon is developing lubricants offering high performance, biodegradability and bio-based content Oleon operates 5 manufacturing facilities: four in Europe and one in Malaysia The addressable market for succinic acid in specialty lubricants is estimated to be $100 million MINNEAPOLIS , Dec.
Sign-up for BioAmber Signs Exclusive Supply Agreement for Bio-Succinic Acid in Lubricants investment picks
Bioanalytical Systems, Inc. (NASDAQ:BASI) announced today that it will now report fourth quarter and full year 2014 financial results prior to the market opening on Monday, December 22, 2014.
Sign-up for Bioanalytical Systems to Release Fourth Quarter Fiscal 2014 Results on Monday December 22, 2014; Conference Call & Webcast Set For 11:00 a.m. EST investment picks
Bioanalytical Systems, Inc. (NASDAQ:BASI) will release financial results for the fourth quarter of fiscal 2014 ended September 30, 2014 at approximately 8:30 a.m. EST on Wednesday, December 17, 2014.
Sign-up for Bioanalytical Systems to Release Fourth Quarter Fiscal 2014 Results on Wednesday December 17, 2014; Conference Call & Webcast Set For 11:00 a.m. EST investment picks
Bioanalytical Systems, Inc. (NASDAQ:BASI) announced today that Jacqueline Lemke, President and CEO, will present at the Noble Financial Capital Markets Eleventh Annual Equity Conference on Tuesday, January 20, 2015 at 11:00 a.m. EST in Room 1 at the Club Med in Sandpiper Bay, Florida.
Sign-up for Bioanalytical Systems, Inc. to Present at the 11th Annual Noble Financial Capital Markets Equity Conference Tuesday, January 20, 2015 at 11:00 a.m. EST investment picks
SAN DIEGO and NASHVILLE, Tenn., Jan.
Sign-up for Biocept and Insight Genetics Collaborate to Advance Non-Small Cell Lung Cancer Diagnosis and Treatment investment picks
SAN DIEGO and PRINCETON, N.J. and REHOVOT, Israel, Oct.
Sign-up for Biocept and Rosetta Genomics Collaborate to Evaluate microRNAs From Circulating Tumor Cells investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Bing shares the top searches of 2014 to Biocept and Rosetta Genomics Collaborate to Evaluate microRNAs From Circulating Tumor Cells
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent